07:00 , Apr 6, 2009 |  BC Week In Review  |  Clinical News

ACR16: Completed Phase III enrollment

NeuroSearch completed enrollment of 420 patients in the double-blind, placebo-controlled, European Phase III MermaiHD trial evaluating 45 mg of oral ACR16 given once or twice daily for 26 weeks. NeuroSearch gained the compound in its...
07:00 , Mar 9, 2009 |  BC Week In Review  |  Company News

NeuroSearch, Astellas deal

Astellas returned to NeuroSearch exclusive, worldwide rights excluding North America, EU, Norway and Switzerland to ACR16 for schizophrenia, ending its 2005 deal with the biotech. Astellas made the decision after a strategic review of the...
00:46 , May 28, 2008 |  BC Extra  |  Financial News

NeuroSearch raises $17.8 million

NeuroSearch (CSE:NEUR) raised DKK84 million ($17.8 million) through the sale of 300,000 shares to institutional investors at DKK280 per share. The price is a 5% discount to NeuroSearch's close of DKK294 on May 20, the...
07:00 , May 26, 2008 |  BioCentury  |  Finance

Ebb & Flow

Based on its track record of exits from its BioDiscovery 1 and 2 funds during the last eight years, Edmond de Rothschild Investment Partners has raised a new E150 million ($233.8 million) fund in less...
00:38 , May 22, 2008 |  BC Extra  |  Financial News

NeuroSearch to raise $17.6 million

NeuroSearch (CSE:NEUR) proposed to raise DKK84 million ($17.6 million) through the sale of 300,000 shares to institutional investors at DKK280 per share. The price is a 5% discount to Tuesday's close of DKK294, the day...
08:00 , Dec 24, 2007 |  BC Week In Review  |  Clinical News

ACR343: Phase I started

NEUR began a double-blind, placebo-controlled, single-ascending dose, Swedish Phase I trial of oral ACR343 in healthy volunteers. The milestone triggers a SEK75 million payment to former shareholders of Carlsson Research AB , which NEUR acquired...
08:00 , Oct 30, 2006 |  BC Week In Review  |  Company News

Carlsson Research, NeuroSearch deal

NEUR completed its previously announced acquisition of Carlsson Research (see BioCentury, Aug. 28). Carlsson Research AB , Gothenburg, Sweden   NeuroSearch A/S (CSE:NEUR), Ballerup, Denmark   Business: Neurology  ...
07:00 , Oct 23, 2006 |  BioCentury  |  Finance

Ebb & Flow

Nutraceuticals and OTC products are two areas where only a handful of VCs have historically played. But they may have a growing appeal as drugs become more expensive to develop and harder to reimburse. Indeed,...
01:47 , Oct 20, 2006 |  BC Extra  |  Top Story

NeuroSearch raises $67M

NeuroSearch (CSE:NEUR) raised DKK400 million ($67 million) in a rights issue through the sale of about 4 million shares at DKK100. NEUR has three compounds in Phase II testing for depression, ADHD, obesity, epilepsy and...
07:00 , Aug 28, 2006 |  BC Week In Review  |  Company News

NeuroSearch, Carlsson Research deal

NEUR plans to acquire fellow CNS company Carlsson Research for SEK166 million ($23.1 million) in cash and SEK84 million ($11.7 million) in stock. Carlsson shareholders are eligible for up to an additional SEK625 million ($87.1...